309 related articles for article (PubMed ID: 19877981)
1. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality.
Penzner JB; Dudas M; Saito E; Olshanskiy V; Parikh UH; Kapoor S; Chekuri R; Gadaleta D; Avedon J; Sheridan EM; Randell J; Malhotra AK; Kane JM; Correll CU
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):563-73. PubMed ID: 19877981
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
[TBL] [Abstract][Full Text] [Related]
3. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A
J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
5. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Aman MG; Binder C; Turgay A
J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.
Sultan RS; Wang S; Crystal S; Olfson M
JAMA Netw Open; 2019 Jul; 2(7):e197850. PubMed ID: 31348506
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.
Linton D; Barr AM; Honer WG; Procyshyn RM
Curr Psychiatry Rep; 2013 May; 15(5):355. PubMed ID: 23539465
[TBL] [Abstract][Full Text] [Related]
8. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
[TBL] [Abstract][Full Text] [Related]
9. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
[TBL] [Abstract][Full Text] [Related]
10. Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder.
Blader JC; Pliszka SR; Kafantaris V; Foley CA; Crowell JA; Carlson GA; Sauder CL; Margulies DM; Sinha C; Sverd J; Matthews TL; Bailey BY; Daviss WB
J Am Acad Child Adolesc Psychiatry; 2013 Dec; 52(12):1281-93. PubMed ID: 24290461
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
Turgay A; Binder C; Snyder R; Fisman S
Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
[TBL] [Abstract][Full Text] [Related]
12. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.
Farmer CA; Epstein JN; Findling RL; Gadow KD; Arnold LE; Kipp H; Kolko DJ; Butter E; Schneider J; Bukstein OG; McNamara NK; Molina BS; Aman MG
J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):117-124. PubMed ID: 27348211
[TBL] [Abstract][Full Text] [Related]
13. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers.
Pringsheim T; Hirsch L; Gardner D; Gorman DA
Can J Psychiatry; 2015 Feb; 60(2):52-61. PubMed ID: 25886656
[TBL] [Abstract][Full Text] [Related]
14. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
Joseph HM; Farmer C; Kipp H; Kolko D; Aman M; McGinley J; Arnold LE; Gadow KD; Findling RL; Molina BSG
J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):90-99. PubMed ID: 30592635
[TBL] [Abstract][Full Text] [Related]
15. The Effectiveness and Tolerability of Central Nervous System Stimulants in School-Age Children with Attention-Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Across Home and School.
Baweja R; Belin PJ; Humphrey HH; Babocsai L; Pariseau ME; Waschbusch DA; Hoffman MT; Akinnusi OO; Haak JL; Pelham WE; Waxmonsky JG
J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):154-63. PubMed ID: 26771437
[TBL] [Abstract][Full Text] [Related]
16. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic.
Weiss M; Panagiotopoulos C; Giles L; Gibbins C; Kuzeljevic B; Davidson J; Harrison R
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):575-82. PubMed ID: 19877982
[TBL] [Abstract][Full Text] [Related]
17. Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial.
Gadow KD; Brown NV; Arnold LE; Buchan-Page KA; Bukstein OG; Butter E; Farmer CA; Findling RL; Kolko DJ; Molina BS; Rice RR; Schneider J; Aman MG
J Am Acad Child Adolesc Psychiatry; 2016 Jun; 55(6):469-78. PubMed ID: 27238065
[TBL] [Abstract][Full Text] [Related]
18. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
Farmer CA; Brown NV; Gadow KD; Arnold LE; Kolko DG; Findling RL; Molina BS; Buchan-Page KA; Rice RR; Bangalore SS; Bukstein O; Rundberg-Rivera EV; McNamara N; Aman MG
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):213-24. PubMed ID: 25885011
[TBL] [Abstract][Full Text] [Related]
19. Off-label second generation antipsychotics for impulse regulation disorders: a review.
Scheltema Beduin A; de Haan L
Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
[TBL] [Abstract][Full Text] [Related]
20. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.
Gadow KD; Arnold LE; Molina BS; Findling RL; Bukstein OG; Brown NV; McNamara NK; Rundberg-Rivera EV; Li X; Kipp HL; Schneider J; Farmer CA; Baker JL; Sprafkin J; Rice RR; Bangalore SS; Butter EM; Buchan-Page KA; Hurt EA; Austin AB; Grondhuis SN; Aman MG
J Am Acad Child Adolesc Psychiatry; 2014 Sep; 53(9):948-959.e1. PubMed ID: 25151418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
